SCHEMBL6520241

SCHEMBL6520241

COc1ccc(S(=O)(=O)c2c[nH]c3ccc(Oc4c(Br)cc(CS(=O)(=O)O)cc4Br)cc23)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.56
SMN1; SMN2 Q16637 4/20 0.48
HTT P42858 3/20 0.48
LMNA P02545 3/20 0.48
TP53 P04637 2/20 0.45
KDM4E B2RXH2 3/20 0.42
POLB P06746 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MEN1 O00255 6/20 0.40
KMT2A Q03164 6/20 0.40
PRKAB2 O43741 1/20 0.39
PRKAG1 P54619 1/20 0.39
PRKAA2 P54646 1/20 0.39
PRKAA1 Q13131 1/20 0.39
PRKAG3 Q9UGI9 1/20 0.39
PRKAG2 Q9UGJ0 1/20 0.39
PRKAB1 Q9Y478 1/20 0.39
RXFP1 Q9HBX9 2/20 0.39
THRA P10827 1/20 0.38
THRB P10828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6520056 0.92 MAPT (0.59) MAPTSMN1; SMN2HTTLMNATP53
SCHEMBL6514370 0.90 SMN1; SMN2 (0.50) MAPTSMN1; SMN2HTTLMNATP53
SCHEMBL6516325 0.90 SMN1; SMN2 (0.50) MAPTSMN1; SMN2HTTLMNATP53
SCHEMBL6514290 0.90 MAPT (0.45) MAPTSMN1; SMN2HTTLMNATP53
SCHEMBL6512092 0.89 MAPT (0.60) MAPTSMN1; SMN2HTTLMNATP53
SCHEMBL6516630 0.89 MAPT (0.56) MAPTSMN1; SMN2HTTLMNATP53
SCHEMBL6860610 0.89 MAPT (0.43) MAPTSMN1; SMN2HTTLMNATP53
SCHEMBL6514265 0.88 MAPT (0.44) MAPTSMN1; SMN2HTTLMNATP53
SCHEMBL6512804 0.88 MAPT (0.55) MAPTSMN1; SMN2HTTLMNATP53
SCHEMBL6524668 0.86 MAPT (0.53) MAPTSMN1; SMN2HTTLMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032874-A1 Anticholesterol agents; arteriosclerosis BAYER AKTIENGESELLSCHAFT (DE) 2005-02-10 US disclosed
US-6794406-B2 FOR THERAPY AND PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA BAYER AKTIENGESELLSCHAFT (DE) 2004-09-21 US disclosed
US-20030078288-A1 Indole derivatives BAYER AKTIENGESELLSCHAFT (DE) 2003-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078288-A1 Indole derivatives IDO1, IDO2, TPH2 MAPT 839/4885SMN1; SMN2 4749/4885HTT 399/4885
US-20050032874-A1 Anticholesterol agents; arteriosclerosis HMGCR, CYP46A1, EBP MAPT 3453/4885SMN1; SMN2 4875/4885HTT 1524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.